Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a randomized, blinded, placebo-controlled trial to evaluate the safety, tolerability
and immunological profile of INO-4500 administered by intradermal (ID) injection followed by
electroporation (EP) using CELLECTRA™ 2000 device in healthy volunteers in Ghana.